The Challenging world of cytopenias: Distinguishing myelodysplastic syndromes from other disorders of marrow failure

Amy Dezern, Mikkael A. Sekeres

Research output: Contribution to journalArticle

Abstract

Over the past decade, our understanding of bone marrow failure has advanced considerably. Marrow failure encompasses multiple overlapping diseases, and there is increasing availability of diagnostic tools to distinguish among the subtypes. Identification of genetic alterations that underlie marrow failure has also greatly expanded, especially for myelodysplastic syndromes. Molecular markers are increasingly used to guide the management of myelodysplasia and may distinguish this diagnosis from other marrow failure disorders. This review summarizes the current state of distinguishing among causes of marrow failure and discusses the potential uses of multiple diagnostic and prognostic indicators in the management of myelodysplastic syndromes and other bone marrow failure disorders.

Original languageEnglish (US)
Pages (from-to)735-745
Number of pages11
JournalOncologist
Volume19
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Myelodysplastic Syndromes
Bone Marrow

Keywords

  • Aplastic anemia
  • Bone marrow failure
  • Large granular leukemia
  • Molecularmarkers
  • Myelodysplastic syndrome
  • PNH
  • SNP array

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

The Challenging world of cytopenias : Distinguishing myelodysplastic syndromes from other disorders of marrow failure. / Dezern, Amy; Sekeres, Mikkael A.

In: Oncologist, Vol. 19, No. 7, 2014, p. 735-745.

Research output: Contribution to journalArticle

@article{6556befc913c40dc9191575cb8726fd2,
title = "The Challenging world of cytopenias: Distinguishing myelodysplastic syndromes from other disorders of marrow failure",
abstract = "Over the past decade, our understanding of bone marrow failure has advanced considerably. Marrow failure encompasses multiple overlapping diseases, and there is increasing availability of diagnostic tools to distinguish among the subtypes. Identification of genetic alterations that underlie marrow failure has also greatly expanded, especially for myelodysplastic syndromes. Molecular markers are increasingly used to guide the management of myelodysplasia and may distinguish this diagnosis from other marrow failure disorders. This review summarizes the current state of distinguishing among causes of marrow failure and discusses the potential uses of multiple diagnostic and prognostic indicators in the management of myelodysplastic syndromes and other bone marrow failure disorders.",
keywords = "Aplastic anemia, Bone marrow failure, Large granular leukemia, Molecularmarkers, Myelodysplastic syndrome, PNH, SNP array",
author = "Amy Dezern and Sekeres, {Mikkael A.}",
year = "2014",
doi = "10.1634/theoncologist.2014-0056",
language = "English (US)",
volume = "19",
pages = "735--745",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "7",

}

TY - JOUR

T1 - The Challenging world of cytopenias

T2 - Distinguishing myelodysplastic syndromes from other disorders of marrow failure

AU - Dezern, Amy

AU - Sekeres, Mikkael A.

PY - 2014

Y1 - 2014

N2 - Over the past decade, our understanding of bone marrow failure has advanced considerably. Marrow failure encompasses multiple overlapping diseases, and there is increasing availability of diagnostic tools to distinguish among the subtypes. Identification of genetic alterations that underlie marrow failure has also greatly expanded, especially for myelodysplastic syndromes. Molecular markers are increasingly used to guide the management of myelodysplasia and may distinguish this diagnosis from other marrow failure disorders. This review summarizes the current state of distinguishing among causes of marrow failure and discusses the potential uses of multiple diagnostic and prognostic indicators in the management of myelodysplastic syndromes and other bone marrow failure disorders.

AB - Over the past decade, our understanding of bone marrow failure has advanced considerably. Marrow failure encompasses multiple overlapping diseases, and there is increasing availability of diagnostic tools to distinguish among the subtypes. Identification of genetic alterations that underlie marrow failure has also greatly expanded, especially for myelodysplastic syndromes. Molecular markers are increasingly used to guide the management of myelodysplasia and may distinguish this diagnosis from other marrow failure disorders. This review summarizes the current state of distinguishing among causes of marrow failure and discusses the potential uses of multiple diagnostic and prognostic indicators in the management of myelodysplastic syndromes and other bone marrow failure disorders.

KW - Aplastic anemia

KW - Bone marrow failure

KW - Large granular leukemia

KW - Molecularmarkers

KW - Myelodysplastic syndrome

KW - PNH

KW - SNP array

UR - http://www.scopus.com/inward/record.url?scp=84903578246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903578246&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2014-0056

DO - 10.1634/theoncologist.2014-0056

M3 - Article

C2 - 24899643

AN - SCOPUS:84903578246

VL - 19

SP - 735

EP - 745

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 7

ER -